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Abstract
The B cell antigen receptor (BCR) efficiently facilitates the capture and processing of 
a specific antigen for presentation on MHC class II molecules to antigen specific CD4+ T cells 
. Despite this, the majority of B cells are only thought to play a limited role in CD4+ T cell 
activation since BCRs are clonotypically expressed. Here we show, however, that activated B 
cells can, both in vitro and in vivo, rapidly donate their BCR to bystander B cells, a process 
that is mediated by direct membrane transfer between adjacent B cells and is amplified by the 
interaction  of the BCR with specific  antigen.  This results  in a dramatic  expansion in the 
number of antigen-binding B cells  in vivo, with the transferred BCR endowing recipient B 
cells with the ability to present specific antigen to antigen-specific CD4+ T cells.
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Introduction
The  activation  of  antigen-specific  CD4+ T  cells  relies  on  the  capacity  of  antigen 
presenting cells (APCs) to internalise and present antigen, as peptide fragments,  on MHC 
class II (MHC-II) molecules. Dendritic cells (DCs) are regarded as the most potent APC  but 
B cells expressing a BCR specific for a particular antigen are also extremely proficient at 
capturing  and presenting  antigen  to  antigen-specific  CD4+ T  cells  .  This  arises  from the 
remarkable  efficiency of  the  BCR in capturing  a  specific  antigen and facilitating antigen 
delivery to MHC-II-rich compartments which specialise in the generation of MHC-II-peptide 
complexes . However, since BCRs are clonotypically produced within a large repertoire of B 
cells, it has been generally accepted that the majority of B cells play only a minor role in 
presenting antigen to T cells .
Recent  reports  have  demonstrated  that  a  number  of  cell  types,  including 
pheochromocytoma cell lines , DCs , T cells , natural killer cells  and B cell lymphomas  have 
the capacity to transfer membrane and cellular components. In the case of B cell lymphomas, 
membrane exchange is thought to be due to transfer of membrane components during direct 
cell  contact   and  possibly  via  membrane  nanotubes  (also  referred  to  as  cytonemes)  ,  in 
processes that are enhanced by BCR crosslinking. Since the most unique difference between 
antigen-specific B cells is their BCR, membrane exchange may allow the exquisite antigen 
binding and processing capacity of one B cell to be transferred to another via BCR transfer. 
By  this  means  it  can  be  postulated  that  BCR transfer  from  antigen-specific  B  cells  to 
bystander B cells during immune responses could enhance the capacity of the local B cell 
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pool  to  specifically  bind  and  present  antigen,  a  process  which  may  greatly  enhance  the 
development of CD4+ T cell responses. In the present study we examined the potential of B 
cells to exchange their BCRs and how this affects their capacity to present specific antigen.
Results
B cells share BCRs following activation
The demonstration  of  membrane  exchange between B cell  lymphomas upon BCR 
cross-linking  suggests that BCRs may be transferred between B cells upon cell activation. To 
assess this possibility, we cultured splenocytes from hens egg lysozyme (HEL)-specific BCR-
transgenic  (Tg)  MD4  mice   with  splenocytes  from  C57BL/6  (B6).CD45.1  mice  in  the 
presence  of  the  B  cell  mitogen,  LPS.  B  cells  from  each  of  the  two  populations  were 
discriminated on the basis of CD45 allotypic differences and BCR exchange determined by 
changes in the cell surface expression of immunoglobulin (Ig)M allotypes as B6.CD45.1 B 
cells express the ‘b’ allotype of IgM (IgMb) whereas the MD4 B cells carry the ‘a’ allotype of 
IgM (IgMa). Using this approach we observed substantial transfer of IgMa to B6.CD45.1 B 
cells and a concomitant transfer of IgMb to MD4 B cells (Figure 1A), with the acquisition of 
donor IgM steadily increasing over 3 days of culture. Negligible BCR transfer was observed 
in the absence of LPS but similar BCR transfer was observed when specific antigen in the 
presence of antigen-specific T helper cells or T helper cell signals, were used to activate B 
cells  (Figure  S1A  and  S1B  in  Supporting  Information).  BCR transfer  was  found  to  be 
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restricted to B cells as B220-negative cells acquired negligible amounts of donor IgM (Figure 
1B).
BCR transfer is rapid, is not due to secreted Ig and is enhanced by specific antigen
The rate of BCR transfer between B cells was assessed by mixing whole cultures of 
LPS-activated MD4 and B6.CD45.1 splenocytes and determining IgMa transfer to B6.CD45.1 
B cells  over  short  periods  of  co-culture  (Figure  2A).  At  37  oC substantial  BCR transfer 
occurred within 10-20 min and by 60 min B6.CD45.1 B cells had gained ~60% of the IgMa 
levels that they had acquired after 3 days of continuous culture with MD4 splenocytes (Figure 
2A). Similar IgMa transfer was observed with washed activated MD4 splenocytes, whereas 
low  IgMa transfer  was  observed  with  the  MD4 culture  supernatant  (CSN),  this  residual 
activity being completely depleted when CSN was passed through an 800nm filter (Figure 
2A). Intriguingly, rapid BCR transfer also occurred after 1 hr incubation at 4 oC, conditions 
which normally inhibit endocytic and exocytic processes, including Ig secretion  (Figure 2A). 
Indeed, we have found that activated B cells from µs-/- mice, which express surface IgMa but 
have essentially no capacity to secrete IgMa , have a similar capacity to transfer their BCRs 
relative to wild type IgMa secretors (Figure 2B). These results indicate that IgM transfer is not 
due to IgM secretion.
Freshly isolated B cells were unable to transfer their BCRs, whereas LPS-activated B 
cells  could readily  donate BCRs to  both non-activated and activated B cells  (Figure  2C), 
although only viable B cells  mediated transfer  (Figure  S2).  Furthermore,  the presence of 
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specific  antigen  (HEL),  but  not  an  unrelated  antigen  (ovalbumin,  (OVA)),  substantially 
increased  the  transfer  of  HEL-specific  IgMa to  both  LPS-activated  and  freshly  isolated 
bystander B cells (Figure 2D). BCR transfer, therefore, appears to be dependent on donor B 
cell activation, does not require recipient B cell activation and can be further enhanced by 
BCR-specific antigen.
BCR donation to bystander B cells involves membrane transfer
It  appears  likely that BCR transfer  is mediated by membrane donation.  Consistent 
with this we observed that CD45.2 molecules and cell surface molecules covalently labelled 
with fluorescein were also transferred from MD4 cells to B6.CD45.1 B cells and those B cells 
that had acquired higher levels of these surface molecules were also the same B cells that 
gained  higher  levels  of  IgMa,  suggesting  co-transfer  of  the  molecules  (Figure  3A). 
Furthermore, by labelling the activated MD4 B cells with the membrane intercalating dye, 
PKH-26, we could directly show membrane transfer in parallel with transfer of IgMa (Figure 
3B).  This  was  further  enhanced  by  the  addition  of  BCR-specific  antigen  over  a  wide 
concentration range (Figure 3B). These results suggest that membrane donation between B 
cells is responsible for BCR transfer.
Confocal  microscopy  was  used  to  directly  visualise  membrane  exchange  between 
PKH-26-labelled activated MD4 B cells and activated EGFP+ B cells (Figure 3C). PKH-26+ 
and EGFP+ B cells rapidly formed cell aggregates (Figure 3Ci and 3Cii) and diffusion of 
PKH-26 into the membranes of recipient EGFP+ B cells  was evident,  suggesting PKH-26 
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labelled  membranes  were  redistributing  into  the  membranes  of  adjacent  EGFP+ B  cells. 
Analysis  of  the  interaction  between  LPS-activated  lymphocytes  and  bystander  resting 
lymphocytes by transmission (TEM) and scanning electron microscopy (SEM) revealed close 
association  between  plasma  membranes  after  cell  mixing  (Figure  S3),  with  membranous 
nanotube-like extensions also connecting the cells.  Intriguingly,  attempts to  interfere with 
most of the known molecular processes involved in membrane fusion and exchange (recently 
reviewed in ) had no inhibitory effect on BCR transfer (Figure S4).
Bystander  B  cells  that  acquire  an  antigen-specific  BCR  gain  the  ability  to  present 
antigen to CD4+ T cells
To  test  if  the  donated  BCR  could  enhance  antigen  presentation  we  assessed  the 
capacity of bystander B cells, after they had acquired the BCR from antigen (HEL)-specific B 
cells, to stimulate CD4+ T cells specific for the same antigen. Purified B cells from CBA/H 
(H-2k) and EGFP+ MD4 mice were co-cultured, under activating conditions, to allow transfer 
of the HEL-specific BCR of the MD4 B cells to the bystander CBA/H B cells. The different B 
cell populations were separated by flow cytometry and after pulsing with HEL assessed for 
their  ability  to  stimulate  CFSE-labelled  HEL-peptide/I-Ak complex-specific  CD4+ T  cells 
from TCR-Tg 3A9 mice .  This revealed that CBA/H B cells  that had acquired the HEL-
specific BCR stimulated, over a 1000-fold antigen dose range, a substantial proportion (up to 
70%) of the HEL-specific CD4+ T cells to up-regulate CD69 and proliferate based on CFSE 
dilution (Figure 4). In contrast, the CBA/H B cells that were not co-cultured with the MD4 B 
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cells induced only a low proportion of the HEL-specific T cells to up-regulate CD69 and 
proliferate. The enhanced T cell responses induced by CBA/H B cells could not be attributed 
to contaminating MD4 B cells since the sorted CBA/H B cell population was of high purity 
(<1% EGFP+ cells, data not shown) and MD4 B cells lacked the appropriate I-Ak MHC-II for 
effective antigen presentation.
Antigen-specific  B  cells  can  donate  their  BCR  to  bystander  B  cells  during  antigen 
specific immune responses in vivo
To assess whether BCR transfer occurs in vivo, an antigen-specific immune response 
was initiated in mice. Freshly isolated CFSE-labelled MD4 spleen cells, mixed with a HEL-
OVA antigen conjugate and LPS, were injected i.v. into B6.CD45.1 recipient mice containing 
adoptively  transferred  CFSE-labelled  OVA-peptide/I-Ab complex-specific  TCR-Tg  OT-II 
lymphocytes  to provide cognate T cell help. The IgMa expression on all CD45.2+ (donor) and 
CD45.2- (host) leukocytes was monitored over a 7 day period (Figure 5Ai). This showed that 
at day 3 after adoptive transfer, the MD4 B cells had begun to donate their BCR to bystander 
B cells, with ~28% of the host B cell pool expressing IgMa at this time point. This correlated 
with extensive MD4 B cells proliferation (Figure 5Aii). The MD4 B cells did not proliferate 
much further over the next 4 days but the number of host B cells acquiring IgMa increased to 
39% on day 4 and was maintained at approximately one third of the B cell pool over the next 
3 days (Figure 5Ai and 5Aii).  As observed  in vitro,  in vivo BCR sharing was essentially 
limited to B220+ cells (Figure 5Ai). BCR transfer was also considerably enhanced 1 hr after 
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challenging the animals with the BCR-specific antigen (i.e.,  63% of the bystander B cells 
acquired the donor BCR, Figure 5B). CD45.2 transfer to host B6.CD45.1 B cells was also 
evident in vivo, a finding consistent with membrane transfer (Figure 5C). Indeed, co-staining 
for both IgMa and CD45.2 revealed that host B cells appeared to have acquired both markers 
in parallel and this coincidental transfer increased not only after in vivo challenge with HEL 
but  also  after  ex  vivo exposure  of  B  cells  for  1  hr  at  4  oC  to  a  wide  range  of  HEL 
concentrations. Recipient B cells that had acquired the HEL-specific BCR also gained the 
ability to present antigen to CD4+ T cells (Figure S5).
Discussion
In this report we describe a novel mechanism by which bystander B cells can acquire 
an antigen-specific BCRs from activated B cells and gain the ability to capture and present 
specific-foreign antigen, thereby increasing the effective APC pool. BCR transfer is mediated 
by  direct  membrane  donation,  demonstrating  an  important  role  for  membrane  transfer 
between  antigen-specific  and  non-antigen-specific  B  cells  during  immune  responses. 
Recently, there have been several reports indicating that many cell types have the capacity to 
transfer  membrane  and  cellular  components  as  a  form  of  intercellular  communication  , 
although  the  functional  significance  of  this  phenomenon  is  unclear.  It  should  be  noted, 
however, that DCs  and B cells  have been reported to acquire antigen tethered to cell surfaces 
and  efficiently  present  these  to  antigen-specific  T cells.  In  these  cases,  antigen  could  be 
acquired from multiple cell types but uptake appeared to be restricted to DCs  or B cells 
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bearing an antigen-specific BCR  and hence appeared to be recipient, but not donor, driven as 
we have reported here. As with these reports, and despite our own extensive studies (Figure 
S4),  the molecular  basis  of membrane exchange is  uncertain.  However,  our  confocal  and 
electron microscopy studies suggest that plasma membranes from activated and bystander B 
cells may coalesce via short membranous extensions resembling short membrane nanotubes. 
In this regard it should be noted that membrane nanotubes can transfer material between cells 
at temperatures as low as 0.7 oC  and similarly BCR transfer occurs quite efficiently at 4 oC. 
Furthermore, it has been reported that the formation of membrane nanotube–like extensions, 
referred  to  as  cytonemes,  are  increased  upon  BCR  stimulation  ,  which  in  our  study 
significantly enhances BCR transfer.
An intriguing aspect of this study is the speed and magnitude of BCR transfer between 
B cells, even at 4 oC. Once appropriately activated B cells can within minutes share their BCR 
with adjacent B cells, this process being substantially enhanced following BCR engagement 
by specific antigen. Furthermore, in vivo studies revealed that up to two thirds of the splenic 
B cells in recipient animals gained the HEL-specific BCR of the transferred Tg B cells once 
the  Tg B cells  had been  specifically  activated by antigen and CD4+ T helper  cells.  This 
represents at least a 9-16 fold expansion in the number of B cells that can bind significant 
levels of specific antigen. Additional studies revealed that the bystander B cells that acquired 
the HEL-specific BCR could very efficiently present HEL to HEL-specific TCR Tg T cells, 
these B cells being able to stimulate antigen-specific CD4+ T cell responses with >1000 times 
less antigen than bystander B cells that have not acquired specific BCRs. Thus, based on these 
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data, BCR sharing results  in a rapid expansion in the number  of B cells that can present 
specific antigen to T cells. Significantly, a number of studies have identified an important role 
for  B  cells   and,  in  particular,  B  cells  bearing  antigen-specific  BCRs  ,  in  CD4+ T  cell 
responses.  Therefore, we postulate that BCR transfer is an important mechanism by which B 
cells can help facilitate the amplification and development of antigen-specific CD4+ T cells 
during an immune response.
Methods
Animals 
Mice  were  obtained  from  the  Animal  Services  Division,  Australian  National 
University  and  from  the  Australian  Phenomics  Facility  and  were  bred  under  specific 
pathogen-free conditions. Mouse strains used were B6, CBA/H, and B6.CD45.1 (B6 congenic 
for CD45.1). Tg mouse strains were MD4 (BCR-Tg expressing HEL-specific-IgMa and IgDa 
on  a  B6  background  ),  OT-II  (TCR-Tg  specific  for  I-Ab-OVA323-339  peptide  on  a  B6 
background ) and 3A9 (TCR-Tg specific for I-Ak-HEL46-61 peptide on a B10.BR background ). 
The Rosa-EGFP Tg (EGFP-Tg) mice were generated by crossing a Rosa26 stop/flox-EGFP 
mouse (kindly provided by Professor Martyn Goulding, Department of Neurobiology, Salk 
Institute, University of California, San Diego) with a generalised Cre recombinase-expressing 
mouse TNAP Cre , to activate expression of EGFP. Double Tg (MD4/EGFP-Tg) mice were 
also used and were generated by crossing MD4 mice with EGFP-Tg mice.  Secretory IgMa 
deficient B6 mice (µs-/-, ) and 129sv (IgMa) mice were generously provided by Dr. Michael 
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R. Ehrenstein (Department of Rheumatology, University College, London, UK) and tested for 
IgM secretion by ELISA.  Mice were used at 4-20 weeks of age and were housed and handled 
according to the guidelines of the ANU Animal Experimentation Ethics Committee.
Cell preparation and purification 
Leukocytes were obtained from spleen and/or lymph nodes as previously described . 
Leukocyte subsets were purified by magnetic cell separation in LS columns (Miltenyi Biotec, 
Bergisch Gladbach, Germany) using streptavidin-conjugated MicroBeads (Miltenyi Biotec) to 
target biotin-conjugated mAb-labelled cells. CD4+ T cells were enriched from pooled lymph 
nodes as well as spleen, and B cells were enriched from spleen. The cells were incubated with 
biotin-conjugated mAbs (Pharmingen) specific for unwanted cell populations with mAbs used 
for CD4+ T cell enrichment being specific for CD8 (53-6.7), CD11b (M1/70), CD11c (HL3) 
and B220 (RA3-6B2) and with mAbs used for B cell  enrichment  being specific for  CD4 
(GK1.5),  CD8 (53-6.7),  CD11b (M1/70),  CD11c (HL3) and CD90.2 (53-2.1).  Negatively 
selected B cell and T cell populations were found to be 90-98% pure, as assessed by flow 
cytometry.
Fluorescent dye and covalent labelling of cells
Lymphocytes were labelled with the intracellular  dye, 5-(and 6-) carboxfluorescein 
diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) and were cell surface 
labelled  with  LC-N-hydroxysuccinimidyl-fluorescein  (Pierce  Rockford,  IL),  as  previously 
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described for CFSE labelling . PKH-26 (Sigma) labelling was performed according to the 
manufacturers instructions. The UV-excitable dye Hoechst 33258 (Calbiochem, La Jolla, CA) 
was used to discriminate between viable, dead and apoptotic cells . Cells (1-5x106/ml) were 
labelled with 1 µg/ml of Hoechst 33258 for 7 min at 37 0C prior to flow cytometry.
Preparation of HEL-OVA conjugates 
Maleimide-activated OVA (Sigma) was conjugated to sulfhydrylated-HEL (Sigma) to 
generate stable HEL-OVA conjugates. OVA was maleimide activated with a 25-fold molar 
excess  of  succinimidyl  4-(N-maleimidomethyl)cyclohexane-1-carboxylate  (SMCC;  Pierce 
Rockford,  IL).  HEL  was  incubated  with  a  7-fold  molar  excess  of  N-succinimidyl  S-
acetylthioacetate  (SATA;  Pierce)  and  conjugated  SATA  was  de-acetylated  in  0.5  M 
hydroxylamine/25 mM EDTA in PBS (pH 7.4). Activated proteins were then conjugated with 
a 4-fold molar excess of HEL to OVA, before being dialysed against PBS in a 10 kDa cut off 
dialysis bag.
Cell culture, cell culture fractionation and antigen presentation assays
Activated  B  cells  were  generated  by  culturing  purified  B  cells  or  RBC-depleted 
splenocytes (1x106/ml) in supplemented DMEM (sDMEM, Gibco BRL, Grand Island, NY) 
containing  10% fetal  calf  serum (FCS)  as  previously  described   in  6  well  plates  (Nunc, 
Wiesbaden, Germany) in the presence of 10 µg/ml LPS (Sigma) for up to 3 days at 37 0C in 
5%  CO2.  In  some  experiments,  cultures  were  harvested  and  cells  readjusted  to  a  final 
13
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
07
.1
20
7.
1 
: P
os
te
d 
5 
O
ct
 2
00
7
concentration of 1x106  cells/ml for re-incubation in 96 well U-bottomed plates (Nunc) either 
at 37 0C in 5% CO2 or at 4 0C (on ice) for various times. To remove CSN components cells 
were washed at least 3 times with 10 ml of PBS. CSN was harvested by pelleting cells at 
300xg for 5 min and aspirating off 3/4 of the uppermost supernatant. Full removal of cell 
debris was accomplished by filtering CSN through 800 nm cut-off cellulose filters (Millipore, 
Bedford, MA).
For antigen presentation assays, purified CFSE-labelled 3A9 TCR-Tg CD4+ T cells 
(1x105)  were  cultured  with  or  without  1.5x105  purified  B  cells,  in  a  total  of  200µl  of 
sDMEM/10%FCS in 96 well U-bottomed plates (Nunc). B cells were pulsed with HEL on ice 
for 20 min, washed and cultured with CD4+ T cells. Cultures were incubated for 15-18 hr or 
for 3 days, at which time cells were analysed by flow cytometry for CD69 expression and 
CFSE content.
In vivo experimentation
RBC-depleted MD4 splenocytes (3x107), with 10 µg of HEL-OVA and 10 µg of LPS, 
were adoptively transferred via the lateral tail vein into B6.CD45.1 mice in 200 µ  of PBS. 
B6.CD45.1 hosts  had received  i.v.  3x107 RBC-depleted CFSE-labelled lymphocytes  from 
OT-II lymph nodes and spleen 2 hr prior to MD4 adoptive transfer, to provide cognate T cell 
help. Spleen cells from host mice were harvested at various times, depleted of RBC by lysis 
and adjusted to 1-4x107  cell/ml, ready for antibody staining and flow cytometry.  In some 
experiments animals were challenged i.v. with an additional bolus 10 µg of HEL 1 hr prior to 
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spleen harvesting.
Antibody staining
Cells  for  flow  cytometry  analysis  were  stained  on  ice  with  specific  mAbs  and 
secondary  fluorochrome  conjugates  as  previously  described  .   MAbs  specific  for  CD4 
(GK1.5),  CD16/CD32  (2.4G2),  CD45.1  (A20),  CD45.2  (104),  B220/CD45R  (RA3-6B2), 
CD69 (H1.2F3), CD90.2 (53-2.1), Kk (36.7-5), Kb (AF6-88.5), IgMa (DS-1) and IgMb (AF6-
78) were purchased from Pharmingen (Burlingame, CA). The specificity of antibody binding 
and secondary reagents was monitored through the use of isotype matched control antibodies 
(eBioscience, San Diego, CA).
Flow cytometry 
Analytical  flow cytometry  was performed  in  a  LSR (Becton Dickinson,  Mountain 
View, CA), modified with a yellow He-Ne laser emitting a spectral line at 594nm (Research 
Electro-Optics, Inc. Boulder, CO) and cell sorting to purify B cell populations was performed 
using a FACStar plus (Becton Dickinson) or a FACSVantage with the DiVa option (Becton 
Dickinson).  Unless  otherwise  indicated,  statistical  analysis  of  the  proportion  of  a  cell 
population expressing a marker was based on histogram profiling using Overton subtraction 
as applied by FlowJo software (Tree Star, OR).
15
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
07
.1
20
7.
1 
: P
os
te
d 
5 
O
ct
 2
00
7
Confocal Microscopy
Confocal microscopy was performed with a Radiance Confocal Microscope (BioRad) 
using the Argon 488 nm laser as the source of excitation. For live cell imaging, 1x105 LPS 
activated  MD4 splenic  B  cells,  pre-labelled  with  PKH-26  and  a  Cy-Chrome–conjugated 
B220-specific  mAb,  were  added  to  5x105 Cy-Chrome–conjugated  B220-specific  mAb-
labelled LPS-activated EGFP-Tg splenic B cells on a cooling stage set at 4  0C and images 
taken for 60 min.
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Figure 1. B cells exchange BCRs following prolonged activation by LPS
(A) B6.CD45.1 and MD4 spleen cells were co-cultured in the presence of LPS. Dot plots 
show expression of IgMa and IgMb on live (Hoechst 33258low) CD45.1+ (red) and CD45.1- 
(black) B220+ cells over 3 days. Values are percentage of B6.CD45.1 B cells expressing IgMa 
(red) or MD4 B cells expressing IgMb (black) relative to background expression on B cells 
cultured independently (represented by quadrant gates). (B) Transfer of IgMa to B6.CD45.1 
B220+ cells and B220- cells after 3 days culture with MD4 cells (red open histograms). Grey 
filled  histogram  represents  background  IgMa staining  of  B6.CD45.1  splenocytes  cultured 
alone and black open histogram depicts IgMa expression on MD4 B cells.
Figure 2. Activated B cells rapidly transfer BCRs to both resting and activated B cells through 
non-soluble factors in a process enhanced by specific antigen
(A) Fractions of day 3 LPS-activated MD4 spleen cell cultures were added to 3 day LPS-
activated B6.CD45.1 spleen cells and incubated at 37 0C for up to 2 hr or at 4  0C for 1 hr. 
Percentage B6.CD45.1 B cells expressing IgMa was assessed as in Fig. 1A and IgMa transfer 
represented as a proportion (%) of IgMa transfer over 3 days continuous co-culture. MD4 cell 
culture fractions included whole culture, MD4 cells washed to remove soluble factors, MD4 
culture  supernatant  (CSN)  depleted  of  cells  by  centrifugation  and  the  cell-depleted  CSN 
passed through a 800 nm filter. (B) The capacity of B cells from µs-/- mice to transfer IgMa to 
B6 B cells after continuous co-culture for 3 days at 37 oC or after brief (3hr) co-incubation at 
4 oC. For 3 day incubations, B6 spleen cells (IgMb) were co-cultured with spleen cells from µ
s-/- mice (IgMa) or 129sv (µs+/+) mice (the founder strain for the IgMa expressed in µs-/- mice 
but  which  can  secrete  IgMa)  in  the  presence  of  LPS.  For  brief  incubations,  3  day  LPS 
activated spleen cells were incubated together for ~3 hr. B6 B cells were then assessed for 
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IgMa surface expression. Numbers are the percentage of B6 B cells expressing IgMa after co-
culture with donor  B cells relative to IgMa expression by B6 B cells cultured alone.  The 
histogram depicts the concentration of IgM in the culture supernatants of either µs-/- or µs+/+ 
splenocytes cultured for 3 day with LPS. (C) Day 3 LPS-activated MD4 spleen cells were 
incubated with either 3 day LPS-activated or freshly isolated B6.CD45.1 spleen cells for 1 hr 
at 4 oC.  B cells were then assessed for IgMa and IgMb surface expression. Numbers are the 
percentage  of  B  cells  expressing  non-endogeneous  IgM.  (D)  Day  3  LPS-activated  MD4 
spleen cells were incubated with LPS-activated B6.CD45.1 spleen cells in the presence of 
HEL or  OVA for  1  hr  at  4  oC. B6.CD45.1 B cells  were  then assessed for  IgMa surface 
expression  represented  as  a  proportion  (%)  of  IgMa transfer  over  3  days  continuous  co-
culture. Data in (A), (C) and (D) are representative of 3 independent experiments.≥
Figure 3. BCR transfer occurs concomitantly with transfer of other membrane components
(A)  Upper  Panels:  Simultaneous  expression  of  IgMa and  CD45.2  on  B6.CD45.1  B cells 
cultured  with  MD4 B cells  for  3  days  with  LPS.  The  percentage  of  B6.CD45.1  B cells 
positive for IgMa and CD45.2 after co-culture with MD4 B cells is shown adjacent to the 
respective axis for each marker. The boxed area represents background staining for CD45.2 
and IgMa of B6.CD45.1 spleen cells cultured alone. Lower Panels: Simultaneous transfer of 
IgMa and pre-labelled MD4 surface molecules to resting B6.CD45.1 B cells.  Day 3 LPS-
activated MD4 spleen cells were covalently cell surface labelled with fluorescein and pre-
labelled with antibodies to IgMa and CD45.2. After extensive washing, cells were incubated 
for 1 hr at 37 oC with freshly isolated B6.CD45.1 spleen cells pre-labelled with antibodies to 
B220  and  CD45.1,  and  immediately  analysed  by  flow  cytometry.  The  percentage  of 
B6.CD45.1 B cells positive for IgMa and fluorescein is shown as in the upper panels. The 
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boxed area represents background staining for IgMa and background fluorescein fluorescence 
of  freshly  isolated  B6.CD45.1  spleen  cells.  (B)  Day  3  LPS-activated  MD4 spleen  cells, 
labelled with PKH-26, were incubated with day 3 LPS-activated B6.CD45.1 spleen cells for 1 
hr at 4 0C in the presence of various concentrations of HEL. B cells were then assessed for 
expression of PKH-26 and IgMa (lower panels). Numbers are the percentage of B6.CD45.1 B 
cell expressing each marker. (C) Day 3 LPS-activated MD4 spleen cells were stained with 
PKH-26 and an anti-B220 mAb and incubated on a cooling stage set at 4 0C with anti-B220 
mAb  labelled  day  3  LPS-activated  EGFP-Tg  spleen  cells  and  analysed  by  confocal 
microscopy.   Red = PKH-26, green = EGFP and white bar  = 5µm.  (i-ii)  Green and red 
channel  merging  of  simultaneous  confocal  images  of  B  cells  showing  many  membrane 
adhesions between the two B cell populations within 60 min of co-incubation (i = 59 min and 
ii = 17 min).  Arrows show overlap of EGFP and PKH-26 fluorescence within the same focal 
plane.  Data in (A) – (C) are representative of  3 independent experiments.≥
Figure 4. Bystander B cells that acquire an antigen-specific BCR gain the ability to present 
antigen to CD4+ T cells
B cells purified from CBA/H (H-2k) spleen were cultured with LPS in either the absence or 
presence of purified splenic B cells from MD4/EGFP-Tg (H-2b) mice. After 3 days culture 
EGFP+ MD4 B cells were depleted from CBA/H-MD4 B cell co-cultures by flow cytometry. 
CBA/H B cells purified from the co-cultures (CBA/H +/- MD4), as well as CBA/H and MD4 
B cells cultured alone, were then pulsed with HEL for 20 min at 4  oC, washed and equal 
numbers (1.5x105) cultured with 1x105 purified CFSE-labelled CD4+ 3A9 TCR-Tg T cells 
specific for a HEL-peptide presented by I-Ak. After 0.5 days CD4+ T cells were assessed for 
CD69 expression. After 3 days CD4+ T cells were also assessed for CFSE expression, with 
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the numbers in each histogram referring to the percentage of T cells that have entered one or 
more divisions based on CFSE dilution. Data is representative of 3 independent experiments. 
Figure  5. Antigen-specific B cells  transfer  their  BCR to bystander  B cells  in vivo during 
antigen specific immune reactions.
A) CFSE-labelled MD4 spleen cells, together with 10  µg of HEL-OVA and 10 µg of LPS, 
were injected i.v. into B6.CD45.1 mice 2 hr after the i.v. injection of CFSE-labelled OT-II 
lymphocytes. Spleen cells from mice were analysed over the next 7 days by flow cytometry. 
(i)  Dot plots show B220 and IgMa expression on host (CD45.2-;  black events) and donor 
(CD45.2+;  red  events)  cell  populations,  with  numbers  referring  to  the  percentage  of 
splenocytes (boxed region) that are MD4 B cells (B220+, CD45.2+, IgMahigh). Histograms show 
IgMa expression on host B cells (B220+, CD45.2-, CFSE-) and MD4 B cells (B220+, CD45.2+, 
IgMahigh),  and  isotype  control  mAb  binding  to  host  B  cells,  with  numbers  showing  the 
percentage of host cells expressing IgMa relative to the isotype control. (ii) Viable MD4, OT-
II  and  recipient  (host)  B  cells  were  assessed  for  CFSE  expression.  (B)  An  identical 
experiment  to  that  described  in  (A)  except  that  on  day  3  after  commencement  of  the 
experiment one animal was challenged iv with a 10 µg bolus of HEL 1 hr prior to spleen cell 
harvest and marker analysis. (C) As in (A) except that on day 4 after commencement of the 
experiment one animal was challenged iv with a 10  µg bolus of HEL 1 hr prior to spleen 
harvest. In addition spleen cells from a non-HEL injected animal were incubated at 4 oC for 1 
hr in the presence of various amounts of HEL prior to measurement of marker expression. 
Analysis  involved  assessing  expression  of  IgMa and  CD45.2  on  B6.CD45.1  host  B cells 
compared with autofluorescence and isotype control mAb binding (boxed region). Numbers 
are  the  percentage  of  B6.CD45.1  B cells  expressing  CD45.2  or  IgMa above  background 
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levels, with MD4 B cells that express high levels of IgMa and CD45.2 being gated out of the 
analysis.
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Supporting Information
Bystander  B  cells  Rapidly  Acquire  Antigen  Receptors  from  Activated  B  cells  by 
Membrane  Transfer:  A  Novel  Mechanism  for  Enhancing  Specific  Antigen 
Presentation
Ben J. C. Quah, Vaughan P. Barlow, Virginia McPhun, Klaus I. Matthaei, Mark D. Hulett and 
Christopher R. Parish
Figure S1A. CD40L stimulation induces BCR transfer to bystander B cells
B6.CD45.1 splenocytes (expressing both IgMb and CD45.1) were labelled with CFSE (5µM) 
and  then  co-cultured  with  MD4 splenocytes  (expressing  both  a  HEL-specific  IgMa,  IgDa 
transgene on a C57BL/6 background and CD45.2) for 3 days with CD40L (prepared from 
CD40L-baculovirus-infected Sf9 cell membranes, as described in Supplemental Methods, and 
used at amounts generating maximal B cell proliferation),  IL-4 (50 ng/ml, Peprotech Inc., 
Rocky Hill) and HEL (1 µg/ml). Both B6.CD45.1 and MD4 splenocytes were also cultured 
alone as controls.  B cell blasts were then analysed by flow cytometry for IgMa, with regions 
gated on the basis of single colour control samples as shown.  Note the substantial increase in 
IgMa expression on B6.CD45.1 (CFSE+) B cells after co-culture with MD4 B cells.
Figure S1B. Activation of B cells by T helper cells can induce BCR transfer to bystander 
B cells
EGFP+ spleen  cells  from  HEL-specific  BCR-Tg  (MD4/EGFP-Tg)  mice  (2x106/ml)  were 
cultured with spleen cells from OVA-specific TCR-Tg OT-II mice (2x106/ml) in the presence 
of the conjugated antigen HEL-OVA.  B cells from each population were then monitored for 
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MD4 (Donor)-derived IgMa expression after 3 days of co-culture (expressed as a % relative to 
fluorescent controls).  B cells from OT-II spleen cells (Recipient B cells) cultured alone were 
used as a control to monitor background levels of IgMa expression.  These cultures showed 
that  in  the  presence  of  increasing  concentrations  of  specific  antigen,  which  resulted  in 
increasing activation of the OT-II T cells and MD4 B cells (data not shown), there was a 
dramatic increase in transfer of IgMa from the MD4 (Donor) B cells to the OT-II bystander 
(Recipient) B cells.
Figure S2. Viable cells but not cell debris, apoptotic cells or dead cells are responsible 
for BCR transfer
Day 3 LPS-activated MD4 spleen cell cultures were separated by flow cytometry into viable, 
dead and apoptotic cells as well as a cell debris fraction based on Hoechst 33258 staining and 
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forward scatter properties (dot plots).  These fractions, as well as the total MD4 spleen cell 
culture, were then incubated with day 3 LPS-activated B6.CD45.1 spleen cells for 1 hr at 4 
0C.  B6.CD45.1 B cells were then assessed for IgMa expression after incubation either in the 
presence of the various MD4 spleen cell culture fractions (black open histogram) or in the 
absence of the fractions (grey filled histogram), with IgMa expression on the different MD4 
B220+ fractions also assessed (grey open histogram).  The percentage of IgMa+ B6.CD45.1 B 
cells, after incubation with the various MD4 fractions, is indicated in each histogram.  Data is 
representative of 4 independent experiments.
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Figure S3.  Electron Microscopy of Cell-Cell Interactions
Day 3 LPS-activated MD4 spleen cells were mixed with freshly isolated B6.CD45.1 spleen 
cells for 40 min on 0.1% poly-L-lysine-coated plastic coverslips and then prepared for EM 
analysis as described in the Experimental Procedures.  Activated lymphocytes (MD4 B cells) 
in contact with resting lymphocytes (B6.CD45.1 cells) were chosen for analysis by SEM (i-
iv)  and  TEM (v  and vi).   Panels  ii,  iv  and  vi  are  magnifications  of  membrane  contacts 
between cells depicted in panels i, iii and v respectively.  The larger cell in each panel, which 
exhibits extensive membrane ruffling by SEM, is a LPS-activated B cell whereas the smaller 
cell  represents  a  resting  B  lymphocyte.   Note  the  close  association  between  the  plasma 
membranes of the interacting lymphocytes and contact between the cells by short nanotube-
like structures.
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Figure S4. Enhancement and Inhibition of BCR Transfer by Various Reagents.
Day 3  LPS-activated  MD4 spleen  cells  were  incubated  with  freshly  isolated  B6.CD45.1 
spleen  cells  for  1-2  hr  in  the  continuous  presence  (C)  of  various  reagents,  and  surface 
expression of IgMa (i.e. MD4-derived IgM) was then assessed on B220+ B6.CD45.1 cells by 
flow cytometry.  In some cases MD4 cells were pre-treated (P) with the various reagents as 
indicated and washed twice before incubation with B6.CD45.1 cells.  The %IgMa+ B6.CD45.1 
B220+ cells  resulting  from  the  treatment  incubations  was  then  divided  by  the  %IgMa+ 
B6.CD45.1 B220+ cells from untreated incubations and multiplied by 100 to give % of normal 
IgMa transfer.   The shaded region indicates the 95% confidence interval around the mean 
IgMa transfer observed in control cultures (based on controls from untreated incubations from 
12  samples  across  4  independent  experiments).   Each  data  value  the  mean  of  1-10 
experiments.
References in Figure relevant to cell membrane exchange:
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Comments on Figure S4.  Additional data on the molecular basis of 
BCR transfer between B cells
In an attempt to define the molecular basis of BCR transfer a large number of 
inhibitors of cell adhesion, membrane integrity and membrane fusion were assessed 
for  their  ability  to  inhibit  BCR donation  to  bystander  cells.   The  culture  system 
entailed mixing LPS-activated transgenic (MD4) B cells with freshly isolated splenic 
B cells and assessing BCR/membrane transfer after co-incubation for 2 hr at 37oC. 
This  system  most  closely  mimics  the  in  vivo situation  where  there  is  rapid 
unidirectional transfer of BCR from activated B cells to bystander naïve B cells.
A total of 26 mAbs or mAb combinations were examined for their ability to 
modify BCR transfer, mAbs being chosen that recognise cell surface molecules on B 
cells.  Particular attention was given to investigating molecules that have been shown 
to be involved in cell adhesion and cell fusion (reviewed in Chen, E.H. & Olsen E.N., 
Science 308, 369-373, 2005), with the same mAb clones being used that have been 
reported  previously  to  block  function.   Also  all  mAbs  were  used  at  saturating 
concentrations.   None of the mAbs tested inhibited BCR transfer,  although a few 
mAbs significantly enhanced BCR transfer, namely anti-CD2, CD19, CD44, CD48 
and CD62L. The effect of the CD19-specific mAb is not surprising as CD19 is a 
signalling molecule that can associate with the BCR and BCR engagement by antigen 
(HEL) also enhances transfer.  CD2 and CD48 represent a receptor-ligand pair that 
may facilitate transfer, CD44 has been implicated in cell fusion whereas the role of 
CD62L requires  further  investigation.   Metabolic  inhibitors  (sodium azide,  4  oC), 
protein kinase C inhibitors (Rottlerin, Gu6976), modifiers of plasma membrane lipid 
organization  (annexin  V,  apolipoprotein-E,  methyl  β-cyclodextrin,  CBZ-D-FFG, 
polyethleneglycol-lipid),  cytoskeleton/microtubule  disrupters  (cytochalasin-B, 
latrunculin-B,  colchicine),  broad  spectrum  ion  channel  blockers 
(hexamethylamiloride, amantadine), gap junction blockers (1-octanol) and inhibition 
of  protein secretion (Brefeldin  A) had little  or  no effect  on transfer.   Soluble N-
ethylmaleimide-sensitive  factor  attachment  protein  receptor  (SNARE)  complexes, 
that  facilitate  intracellular  membrane  fusion,  appeared  to  be  not  involved  as  N-
ethylmaleimide slightly enhanced rather than inhibited transfer.  Fixation of the donor 
MD4 B cells  with glutaraldehyde or  paraformaldehyde prevented  transfer.   Schiff 
base formation has been reported to stabilise cell adhesion (Rhodes, J., Immunology  
Today 17, 436-39, 1996) but the continual presence of high concentrations (170 mM) 
of  lysine,  an  inhibitor  of  Schiff  base  formation,  actually  enhanced BCR transfer. 
Furthermore, reduction of cell surface aldehydes by pre-treatment of donor MD4 B 
cells with sodium borohydride enhanced the rate of BCR transfer (data not shown), a 
result  consistent  with  Schiff  base  formation  interfering  with  BCR/membrane 
exchange between B cells. 
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Figure S5. Antigen-specific B cells transfer their BCR to bystander B cells  in  
vivo during antigen specific immune reactions and convert bystander B cells to 
antigen specific APCs.
Freshly isolated CFSE-labelled MD4 spleen cells, together with 10 µg of HEL-OVA 
and 10 µg of LPS, were injected i.v. into B6.CD45.1 recipient mice 2 hr after the i.v. 
injection of CFSE-labelled OT-II lymphocytes. On day 4, animals were challenged iv 
with a 30 µg bolus of either HEL or HEL-OVA 1 hr prior to spleen harvest.  Spleen 
cells were then labelled with IgMa, B220 and CD45.2 specific mAbs and B6.CD45.1 
B cells (B220+,  CD45.2-) sorted into populations expressing low levels (Low) and 
medium levels (Med) of IgMa by flow cytometry as indicated in the dot plot profile. 
Graded numbers of the different B cell populations, from both HEL and HEL-OVA 
challenged mice,  were  then assessed for  their  capacity to activate,  (CD69+ and/or 
divided  based  on  CFSE dilution),  a  constant  number  (1.5x105)  of  CFSE-labelled 
CD4+ OT-II lymphocytes after 3 days of co-incubation.  Data are representative of 3 
independent experiments.
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Supporting Methods
Electron microscopy
Activated MD4 spleen cells (3 day LPS-activated) were mixed with freshly isolated 
B6.CD45.1 RBC-depleted spleen cells at a concentration of 4 x 107 cells/ml each in 
0.3 ml sDMEM and left to attach to plastic coverslips coated with 0.1 % poly-L-
lysine for 40 min at 37  oC.  Cells were then immediately prepared for transmission 
electron microscopy (TEM) or scanning EM (SEM).  For TEM, samples were fixed in 
2 % glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 2 hr, washed 3 
times in 0.1 M sodium cacodylate buffer and post fixed in 1 % OsO4 in 0.1 M sodium 
cacodylate for 20 min.  After 2 washes in buffer, the samples were dehydrated in a 
graded  ethanol  series  to  100 % ethanol  and  embedded  in  Spurrs  resin  at  70  oC. 
Samples were photographed using a Hitachi H7000 electron microscope at 75 kV. 
For SEM, samples were prepared using the same method as for TEM until the 100 % 
ethanol step.  They were then transferred into 100 % amyl acetate (3 washes) and 
critical point dried.  The samples were coated with gold-palladium and photographed 
using a Hitachi S4500 FESEM at 10 kV.
CD40L preparation
SF9 cells were infected with 10 % v/v recombinant CD40L baculovirus stock (Kindly 
provided by Dr Phil Hodgkin, Walter and Eliza Hall Institute, Melbourne).  After 5 
days at 27 oC in air, infected cell were harvested and sedimented at 300g for 5 min. 
Cells from the equivalent of 1000 ml of 5-day culture were then resuspended in 7 ml 
of homogenisation buffer (20 mM Tris-HCL pH 7.4, 10 mM NaCl, 0.1 mM MgCl2 
0.5  mM  CaCl2,  0.1  mM  PMSF)  and  homogenised  with  a  Polytron  homogeniser 
(Kinematica GmbH, Lucern, Switzerland).  Membranes containing CD40L were then 
enriched  from the  cell  homogenate  by  density  centrifugation  using  a  3  ml  41  % 
sucrose underlay and sedimentation at  96,000g for  1 hr at  4  0C.  The membrane-
containing interface was then collected and washed twice, by diluting the membranes 
up to 10 ml in PBS and centrifugation at 100,000g for 1 hr at 4 0C and removing the 
supernatant.  The final membrane pellet was resuspended in PBS (10 ml/1000 ml of 
infected SF9 cells originally harvested), passed through an 18 gauge needle 15 times, 
aliquoted and stored at –70 0C until use.
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